Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Ginkgo Bioworks, SpaceX, and 370+ companies. 5-min read every Tuesday.
Synthetic biology platform programming cells for agriculture, pharmaceuticals, and materials.
| Industry | Biotechnology |
| Stage | Public |
| IPO Status | Public |
| Valuation | $800M |
| Total Funding | $1.6B |
| Headquarters | Boston, MA |
Aerospace and defense company. Active S-1 filed April 1, 2026 targeting $75B Nasdaq IPO in June 2026 at $1.75T–$2T valuation — largest IPO in history. $15B combined revenue (SpaceX + xAI merger). Starlink: $10B revenue, 10M subscribers. Government contracts with NASA and DoD. 30% retail allocation.
| Industry | Aerospace & Defense |
| Stage | Pre-IPO |
| IPO Status | Public |
| Valuation | $1.75T – $2T |
| Total Funding | $11.9B |
| Headquarters | Hawthorne, CA |
Ginkgo Bioworks is valued at $800M. SpaceX is valued at $1.75T – $2T. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Ginkgo Bioworks has raised $1.6B. SpaceX has raised $11.9B.
Ginkgo Bioworks is currently already public. SpaceX is currently already public. Track both on TechStackIPO for S-1 filings and IPO announcements.
Ginkgo Bioworks operates in Biotechnology, while SpaceX operates in Aerospace & Defense.
Ginkgo Bioworks is a Biotechnology company valued at $800M with $1.6B raised. SpaceX is a Aerospace & Defense company valued at $1.75T – $2T with $11.9B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Ginkgo Bioworks and SpaceX through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.